Vir Biotechnology (VIR) Operating Expenses (2018 - 2026)

Vir Biotechnology has disclosed Operating Expenses across 9 years of filings, most recently posting $132.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $132.3 million, down 7.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $537.6 million (down 19.46% YoY), and the FY2025 annual result was $547.9 million, down 17.16% from the prior year.
• Operating Expenses came in at $132.3 million for Q1 2026 at Vir Biotechnology, up from $112.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $233.7 million in Q3 2024 to a low of $112.0 million in Q4 2025.
• The 5-year median for Operating Expenses is $173.7 million (2025), against an average of $170.3 million.
• Across the five-year window, Operating Expenses surged 59.06% in 2022 and tumbled 33.86% in 2024, its largest moves.
• Vir Biotechnology's Operating Expenses stood at $199.9 million in 2022, then slipped by 22.06% to $155.8 million in 2023, then fell by 16.87% to $129.5 million in 2024, then retreated by 13.54% to $112.0 million in 2025, then gained by 18.1% to $132.3 million in 2026.
• The last three Operating Expenses figures came in at $132.3 million (Q1 2026), $112.0 million (Q4 2025), and $173.7 million (Q3 2025), per Business Quant data.